Content about Neuroscience

February 26, 2014

A study released Wednesday by Rhonda Patrick and Bruce Ames of Children's Hospital Oakland Research Institute demonstrated the impact that vitamin D may have on social behavior associated with Autism Spectrum Disorder.

OAKLAND, Calif. — A study released Wednesday by Rhonda Patrick and Bruce Ames of Children's Hospital Oakland Research Institute demonstrated the impact that vitamin D may have on social behavior associated with Autism Spectrum Disorder. 

August 28, 2013

Pure Encapsulations on Tuesday launched its PureSynapse product line, including SeroPlus, DopaPlus, NeuroPure and Amino Replete, four specialty formulas to support emotional health, memory and behavior that was formulated with James Greenblatt, an author and lecturer who is dedicated to integrative psychiatry.

SUDBURY, Mass. — Pure Encapsulations on Tuesday launched its PureSynapse product line, including SeroPlus, DopaPlus, NeuroPure and Amino Replete, four specialty formulas to support emotional health, memory and behavior that was formulated with James Greenblatt, an author and lecturer who is dedicated to integrative psychiatry.

“As we begin to better understand nutritional deficiencies and toxic environmental chemicals that interfere with brain function, we are better able to provide safe and effective support for mental health,” Greenblatt stated.  

August 8, 2013

With the launch of Procter & Gamble's ZzzQuil, a relatively quiet sleep category has exploded with energy this year. A lot of that has to do with the $121.1 million in sales that ZzzQuil — both tablet and liquid formulations — has generated this year.

With the launch of Procter & Gamble's ZzzQuil, a relatively quiet sleep category has exploded with energy this year. A lot of that has to do with the $121.1 million in sales that ZzzQuil — both tablet and liquid formulations — has generated this year.

But that doesn't explain everything. The entire category is up nearly $145 million. For the 52 weeks ended June 16 across total U.S. multi-outlets, IRI measured a 707.4% lift in sleep liquid sales to $89.7 million. The slightly larger category of sleep tablets realized a 29.8% lift in sales to $294.2 million.

June 11, 2013

Aceto Corp. will sell an authorized generic version of a drug used to treat a rare but devastating degenerative disorder.

PORT WASHINGTON, N.Y. — Aceto Corp. will sell an authorized generic version of a drug used to treat a rare but devastating degenerative disorder.

Aceto said it would launch the authorized generic version of Covis Pharma's Rilutek (riluzole) tablets in the 50-mg strength through its Rising Pharmaceuticals subsidiary. The drug is used to treat amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

Sales of the drug were about $64 million in 2012, according to Aceto.

 

March 5, 2013

Procter & Gamble’s Downy and ZzzQuil brands have joined forces to help consumers create an environment that is conducive for falling asleep in time for National Sleep Awareness Week March 3-10.

CINCINNATI — Procter & Gamble’s Downy and ZzzQuil brands have joined forces to help consumers create an environment that is conducive for falling asleep in time for National Sleep Awareness Week March 3 to 10. 

According to a recent poll by the National Sleep Foundation, 1-in-4 adults report occasional sleeplessness with difficulty falling asleep at least a few times a week. 

March 4, 2013

Sixty-two percent of teenagers say they don't eat breakfast every day of the week, according to a new report released Monday that investigates the link between nutrition, physical activity and academic performance.

ROSEMONT, Ill. — Sixty-two percent of teenagers say they don't eat breakfast every day of the week, according to a new report released Monday that investigates the link between nutrition, physical activity and academic performance.

The report, "The Wellness Impact: Enhancing Academic Success Through Healthy School Environments", was the work of the GENYOUth Foundation, National Dairy Council, the American College of Sports Medicine and the American School Health Association.

February 7, 2013

An insomnia drug made by Purdue Pharma "significantly" reduced the time it took patients to return to sleep after they'd woke up in the middle of the night, according to a new study.

STAMFORD, Conn. — An insomnia drug made by Purdue Pharma "significantly" reduced the time it took patients to return to sleep after they'd woke up in the middle of the night, according to a new study.

The placebo-controlled study, published in the journal Sleep, tested the drug Intermezzo (zolpidem tartrate) sublingual tablets on 295 adults with primary insomnia and difficulty returning to sleep after waking up in the middle of the night. Purdue said Intermezzo was the only drug approved by the Food and Drug Administration for treating such patients.

January 3, 2013

An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said.

WESTON, Mass. — An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said Thursday.

Biogen announced results of its phase-3 trial of dexpramipexole in patients with the disease, known technically as amyotrophic lateral sclerosis, or ALS. The drug failed to improve functioning and survival in patients and failed to show efficacy in key secondary endpoints as well, the company said.

March 19, 2012

Women take mental health drugs at a much higher rate than men, according to a new study by one of the country's largest pharmacy benefit managers.

WASHINGTON — Women take mental health drugs at a much higher rate than men, according to a new study by one of the country's largest pharmacy benefit managers.

Medco Health Solutions released results of the study Monday, showing that 25% of women use psychotropic drugs, compared with 15% of men. The study was based on the pharmacy claims of more than 2 million Americans and measured the use of drugs for treating depression, anxiety, attention deficit hyperactivity disorder and psychotic disorders between 2001 and 2010.

June 30, 2011

Innovation took center stage Thursday as Eli Lilly laid out its future growth strategies at a meeting with investors.

NEW YORK — Innovation took center stage Thursday as Eli Lilly laid out its future growth strategies at a meeting with investors.

At its “Bridging to the Future” meeting, Lilly said it had 70 drugs in its research and development pipeline, including 33 in phases 2 and 3. The company said it expects at least 10 new drugs to enter phase 3 this year, including drugs in such areas as cancer, diabetes and neuroscience, as well as new therapeutic areas, such as autoimmune disorders.